Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.60 |
| ▸ | BACE2 | Q9Y5Z0 | 10/20 | 0.60 |
| ▸ | APP | P05067 | 6/20 | 0.57 |
| ▸ | CTSD | P07339 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8514463 | 1.00 | BACE1 (0.60) | BACE1BACE2APPCTSDCYP3A4 | |
| Hydrochloric Acid SCHEMBL8516224 | 0.99 | BACE1 (0.59) | BACE1BACE2APPCTSDCYP3A4 | |
| Trifluoroacetic Acid SCHEMBL12273105 | 0.92 | BACE1 (0.59) | BACE1BACE2APPCTSDCYP3A4 | |
| SCHEMBL10325776 | 0.89 | BACE1 (0.64) | BACE1BACE2APPCTSDCYP3A4 | |
| SCHEMBL362342 | 0.88 | BACE1 (0.65) | BACE1BACE2APPCTSDCYP3A4 | |
| SCHEMBL361251 | 0.84 | BACE1 (0.54) | BACE1BACE2APPCTSDCYP3A4 | |
| SCHEMBL8514461 | 0.83 | BACE1 (0.59) | BACE1BACE2APPCTSDCYP3A4 | |
| SCHEMBL8515837 | 0.83 | BACE1 (0.59) | BACE1BACE2APPCTSDCYP3A4 | |
| SCHEMBL15644923 | 0.83 | BACE1 (0.57) | BACE1BACE2APPCTSDCYP3A4 | |
| SCHEMBL360542 | 0.83 | BACE1 (0.57) | BACE1BACE2APPCTSDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2663559-B1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-07-01 | — | — | EP | claimed |
| EP-2456763-B1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | claimed |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-15 | — | — | US | claimed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | claimed |
| EP-2663308-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | claimed |
| US-8338413-B1 | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2012-12-25 | — | — | US | claimed |
| EP-2483255-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-08-08 | — | — | EP | claimed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | claimed |
| EP-2456763-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-05-30 | — | — | EP | claimed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | claimed |
| US-10399995-B2 | 1,4-Oxazines useful as selective BACE1 inhibitors | ELI LILLY AND COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399995-B2 | 1,4-Oxazines useful as selective BACE1 inhibitors | ELI LILLY AND COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3504211-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | Eli Lilly and Company (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20190161502-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | LILLY CO ELI (US) | 2019-05-30 | — | — | US | disclosed |
| US-20190161502-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | LILLY CO ELI (US) | 2019-05-30 | — | — | US | disclosed |
| US-20120178745-A1 | Novel Crystalline Oxazine Derivative | NOVARTIS PHARMA AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120172359-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | NOVARTIS AG (CH) | 2012-07-05 | — | — | US | disclosed |
| US-8207164-B2 | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2012-06-26 | — | — | US | disclosed |
| EP-2456763-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | BACE1 2/4885BACE2 1/4885APP 5/4885 |
| US-20120172359-A1 | Oxazine Derivatives and their Use in the Treatment of Neurological Disorders | OTC, GRIK5, GRIN2C | BACE1 69/4885BACE2 161/4885APP 94/4885 |
| US-10399995-B2 | 1,4-Oxazines useful as selective BACE1 inhibitors | BACE1, BACE2, PSEN1 | BACE1 1/4885BACE2 2/4885APP 4/4885 |
| US-20120178745-A1 | Novel Crystalline Oxazine Derivative | CYP3A5, CHRM5, CYP2C8 | BACE1 1737/4885BACE2 1918/4885APP 2048/4885 |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | BACE1 69/4885BACE2 161/4885APP 94/4885 |
| US-20190161502-A1 | 1,4-OXAZINES USEFUL AS SELECTIVE BACE1 INHIBITORS | BACE1, BACE2, PSEN1 | BACE1 1/4885BACE2 2/4885APP 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.